Precision BioSciences Announces Allowance of Third U.S. Patent Related to Engineered Meganucleases
1/30/2012 6:04:56 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office (PTO) has issued a Notice of Allowance for U.S. Patent Application 13/245,607 (“the '607 Application”). The allowed claims relate to methods of cleaving a target DNA site in a cell using an engineered meganuclease. These methods are broadly utilized as a part of Precision’s DNE genome engineering technology.
comments powered by